Biohaven Ltd. (BHVN)
15.29
+0.81
(+5.59%)
USD |
NYSE |
Nov 09, 12:08
Biohaven Net Income (Quarterly) : -129.28M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -129.28M |
| June 30, 2026 | -137.31M |
| March 31, 2026 | -130.53M |
| December 31, 2025 | -145.56M |
| September 30, 2025 | -173.44M |
| June 30, 2025 | -198.15M |
| March 31, 2025 | -221.68M |
| December 31, 2024 | -186.84M |
| September 30, 2024 | -160.30M |
| June 30, 2024 | -319.77M |
| Date | Value |
|---|---|
| March 31, 2024 | -179.50M |
| December 31, 2023 | -144.76M |
| September 30, 2023 | -102.57M |
| June 30, 2023 | -90.35M |
| March 31, 2023 | -70.49M |
| December 31, 2022 | -201.11M |
| September 30, 2022 | -68.85M |
| June 30, 2022 | -203.29M |
| March 31, 2022 | -97.03M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Summit Therapeutics, Inc. | -208.38M |
| Kezar Life Sciences, Inc. | -5.756M |
| Protara Therapeutics, Inc. | -21.69M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 129.28M |
| EPS Diluted (Quarterly) | -0.8559 |
| Enterprise Value | 2.326B |
| Earnings Yield | -25.26% |
| Normalized Earnings Yield | -24.65 |